E M Ohman

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
    E Magnus Ohman
    Division of Cardiology, Duke University Medical Center, Durham, NC, USA
    Am Heart J 151:786.e1-10. 2006
  2. ncbi Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries
    E M Ohman
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 84:1281-6. 1999
  3. ncbi Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
    B E Tardiff
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 33:88-96. 1999
  4. ncbi Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 103:2891-6. 2001
  5. ncbi Cardiac markers: point of care testing
    M P Hudson
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Clin Chim Acta 284:223-37. 1999
  6. ncbi Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III
    M P Hudson
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 104:1229-35. 2001
  7. ncbi Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
    M T Roe
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 102:1101-6. 2000
  8. ncbi Myonecrosis after revascularization procedures
    R M Califf
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 31:241-51. 1998
  9. ncbi Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
    R D Anderson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 30:708-15. 1997
  10. ncbi Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Usin
    J H Alexander
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 283:347-53. 2000

Detail Information

Publications83

  1. ncbi The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
    E Magnus Ohman
    Division of Cardiology, Duke University Medical Center, Durham, NC, USA
    Am Heart J 151:786.e1-10. 2006
    ....
  2. ncbi Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries
    E M Ohman
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 84:1281-6. 1999
    ..Troponin T testing could be a valuable addition to the evaluation strategy for patients with acute myocardial infarction...
  3. ncbi Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
    B E Tardiff
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 33:88-96. 1999
    ....
  4. ncbi Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 103:2891-6. 2001
    ..Troponin T (TnT) is valuable for short- and long-term risk stratification of patients with acute coronary syndromes (ACS). It also may predict which ACS patients will benefit from glycoprotein (GP) IIb/IIIa blockade...
  5. ncbi Cardiac markers: point of care testing
    M P Hudson
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Clin Chim Acta 284:223-37. 1999
    ....
  6. ncbi Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III
    M P Hudson
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 104:1229-35. 2001
    ....
  7. ncbi Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
    M T Roe
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 102:1101-6. 2000
    ..A proportion of patients who present with suspected acute coronary syndrome (ACS) are found to have insignificant coronary artery disease (CAD) during coronary angiography, but these patients have not been well characterized...
  8. ncbi Myonecrosis after revascularization procedures
    R M Califf
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 31:241-51. 1998
    ..In addition, tracking of enzyme levels in clinical trials is needed to determine whether interventions that reduce periprocedural enzyme elevation also improve mortality...
  9. ncbi Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
    R D Anderson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 30:708-15. 1997
    ..We sought to examine the use, complications and outcomes with early intraaortic balloon counterpulsation (IABP) in patients presenting with cardiogenic shock complicating acute myocardial infarction and treated with thrombolytic therapy...
  10. ncbi Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Usin
    J H Alexander
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 283:347-53. 2000
    ..Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation...
  11. ncbi Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit
    L K Newby
    Duke Clinical Research Institute, Durham, North Carolina 27715 7969, USA
    Am J Cardiol 85:801-5. 2000
    ..0001). Thus, cTnT identified more CPU patients with myocardial necrosis and multivessel CAD than CK-MB and a population with high long-term mortality risk. Routine use of cTnT in CPUs could facilitate risk stratification and management...
  12. ncbi Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 98:1853-9. 1998
    ....
  13. ncbi Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
    M G Cohen
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 34:1729-37. 1999
    ..We sought to describe the differences in the process of care and clinical outcomes between Hispanics and non-Hispanics receiving thrombolytic therapy for myocardial infarction (MI)...
  14. ncbi Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions
    R D Anderson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 32:936-41. 1998
    ..We sought to determine the prognostic significance of a history of congestive heart failure above that provided by baseline ejection fraction in patients undergoing percutaneous coronary interventions...
  15. ncbi Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators
    A B Greenbaum
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 37:492-8. 2001
    ....
  16. ncbi Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 37:9-18. 2001
    ..Thus, as the reperfusion era moves into the next millennium, the open-artery hypothesis is expected to shift downstream and guide efforts to further improve myocardial salvage and clinical outcomes after acute MI...
  17. ncbi Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty
    G W Barsness
    Duke Heart Center, Duke University Medical Center, Durham, NC, USA
    Circulation 96:2551-6. 1997
    ..We studied the relationship between diabetes and survival after revascularization in a large prospective cohort of patients with multivessel coronary artery disease...
  18. ncbi Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 103:1832-7. 2001
    ..A multimarker strategy (MMS) testing for several markers of myocardial necrosis with different time-to-positivity profiles also may offer clinical advantages...
  19. ncbi Effectiveness and safety of abciximab after failed thrombolytic therapy
    W J Cantor
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 87:439-42, A4. 2001
    ..53/10 years, 95% CI 1.05 to 2.21, p = 0.03), time from thrombolytic to abciximab (OR 0.91/hour, 95% CI 0.83 to 0.99, p = 0.03), and intra-aortic balloon pump insertion (OR 4.42, 95% CI 2.00 to 9.72, p = 0.0002)...
  20. ncbi Provisional stenting strategies: systematic overview and implications for clinical decision-making
    W J Cantor
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 36:1142-51. 2000
    ..Provisional stenting may potentially reduce costs and rates of in-stent restenosis without compromising the quality of health care delivery...
  21. ncbi Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
    R D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Heart 94:867-73. 2008
    ....
  22. ncbi Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Eur Heart J 25:313-21. 2004
    ..To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  23. ncbi One-year cardiovascular event rates in outpatients with atherothrombosis
    Ph Gabriel Steg
    Departement de Cardiologie, Hopital Bichat Claude Bernard, Paris, France
    JAMA 297:1197-206. 2007
    ....
  24. ncbi Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative
    Adam H Skolnick
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:1790-7. 2007
    ..The goal of this work was to explore the treatment and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) age > or =90 years...
  25. ncbi Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative)
    Prospero B Gogo
    University of Vermont College of Medicine, Burlington, Vermont, USA
    Am J Cardiol 99:1222-6. 2007
    ..Long-term implications of this shift remain uncertain, especially in patients with 3VD...
  26. ncbi Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes
    Kyla M Bennett
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
    Am J Cardiol 99:1351-6. 2007
    ..Guideline-recommended therapies and interventions are under-utilized in patients with NSTE ACS and HF, with and without preserved systolic function, compared with those without HF...
  27. ncbi Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Ger
    Karen P Alexander
    Duke University Medical Center, USA
    Circulation 115:2549-69. 2007
    ..Reasons include limited trial data to guide the care of older adults and uncertainty about benefits and risks, particularly with newer medications or invasive treatments and in the setting of advanced age or complex health status...
  28. ncbi Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Lancet 369:907-19. 2007
    ..The aim of this study was to assess anticoagulation with the direct thrombin inhibitor bivalirudin during percutaneous coronary intervention in individuals with moderate and high-risk acute coronary syndromes...
  29. ncbi Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    JAMA 297:591-602. 2007
    ..The preferred approach is undetermined...
  30. ncbi Bivalirudin for patients with acute coronary syndromes
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 355:2203-16. 2006
    ..We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients...
  31. ncbi The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
    Deborah B Diercks
    Department of Emergency Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA
    Am Heart J 152:140-8. 2006
    ..Although obesity is a known risk factor for coronary artery disease, its impact on the presentation, treatment, and outcome of patients with acute coronary syndromes (ACS) has not been well studied...
  32. ncbi Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early imp
    Mauricio G Cohen
    Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7075, USA
    Am Heart J 152:110-7. 2006
    ..Data regarding the management of non-ST-segment elevation acute coronary syndromes (NSTE ACS) in Hispanic patients, the largest and fastest-growing minority in the United States, are scarce...
  33. ncbi Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative
    Kanwar P Singh
    Division of Cardiology and Duke Clinical Research Institute, Durham, NC 27705, USA
    J Thromb Thrombolysis 21:211-20. 2006
    ....
  34. ncbi Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Jin H Han
    Department of Emergency Medicine, University of Cincinnati School of Medicine, Cincinnati, Ohio, USA
    Am J Med 119:248-54. 2006
    ..We examined the treatment and outcomes of patients with both non-ST-segment elevation acute coronary syndromes and moderate to severe chronic kidney disease...
  35. ncbi Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Am Heart J 151:360-6. 2006
    ..Troponin testing is useful for evaluating patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS); however, a significant percentage of patients are troponin negative at presentation and develop late rise of the marker...
  36. ncbi Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric
    Karen P Alexander
    Duke University Medical Center, USA
    Circulation 115:2570-89. 2007
    ....
  37. ncbi Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative
    Sumit Tickoo
    Bridgeport Hospital, Bridgeport, Connecticut, USA
    Am J Cardiol 99:1496-9. 2007
    ....
  38. ncbi The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale
    Roxana Mehran
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    Am Heart J 156:44-56. 2008
    ..Newer pharmacologic agents and drug-eluting stents may address both of these issues...
  39. ncbi Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Shaun G Goodman
    St Michael s Hospital, Division of Cardiology, 30 Bond Street, Queen, Toronto, Ontario, Canada
    Chest 133:708S-775S. 2008
    ....
  40. ncbi Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology
    James McCord
    Henry Ford Hospital
    Circulation 117:1897-907. 2008
  41. ncbi Risk factor profile and management of cerebrovascular patients in the REACH Registry
    Joachim Rother
    Department of Neurology, Klinikum Minden, Hannover Medical School, Minden, Germany
    Cerebrovasc Dis 25:366-74. 2008
    ..We assessed these factors in 18,992 CVD patients within a worldwide registry of stable outpatients...
  42. ncbi Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su
    Deepu Alexander
    Division of Cardiovascular Medicine, State University of New York, Stony Brook School of Medicine, Stony Brook, NY 11794, USA
    Am Heart J 156:606-12. 2008
    ..We sought to determine patterns of early (<24 hours of arrival) clopidogrel use and its association with clinical outcomes in patients with NSTEMI not undergoing early percutaneous intervention (PCI)...
  43. ncbi Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:991-6. 2008
    ..Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients...
  44. ncbi Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    JAMA 298:2497-506. 2007
    ....
  45. ncbi Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II
    Mohammad I Zia
    Canadian Heart Research Centre, Toronto, Canada
    Can J Cardiol 23:1073-9. 2007
    ..Practice guidelines support an early invasive strategy in patients with non-ST segment elevation acute coronary syndromes, particularly in those at higher risk...
  46. ncbi Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angi
    Adam B Greenbaum
    Henry Ford Heart and Vascular Institute, Detroit, MI, USA
    Am Heart J 154:702-9. 2007
    ..The aim of this study was to assess the safety and coronary artery patency of cangrelor as an adjunct to alteplase (tissue plasminogen activator [t-PA])...
  47. ncbi Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia
    E Marc Jolicoeur
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Curr Cardiol Rep 9:396-405. 2007
    ..The algorithm also integrates preventive measures directed at decreasing the bleeding risk associated with the antithrombotic and invasive therapies used for HIT and percutaneous coronary intervention...
  48. ncbi Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction
    Chadwick D Miller
    Wake Forest University Health Sciences, Winston Salem, NC, USA
    Am J Med 120:685-92. 2007
    ..We sought to determine the impact of acute beta-blocker therapy on outcomes in patients with NSTEMI...
  49. ncbi Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
    Jean-Pierre Bassand
    Eur Heart J 28:1598-660. 2007
  50. ncbi Pay for performance, quality of care, and outcomes in acute myocardial infarction
    Seth W Glickman
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, NC, USA
    JAMA 297:2373-80. 2007
    ..In 2003, the Centers for Medicare & Medicaid Services (CMS) launched the largest pay-for-performance pilot project to date in the United States, including indicators for acute myocardial infarction...
  51. ncbi Medical records and quality of care in acute coronary syndromes: results from CRUSADE
    Shannon M Dunlay
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Arch Intern Med 168:1692-8. 2008
    ..Patient medical records are important means of communication among health care providers. Limited evaluation has been performed of the quality of the medical records or its association with health care processes or outcomes...
  52. ncbi International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 295:180-9. 2006
    ..To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis...
  53. ncbi Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes
    Gerard X Brogan
    Department of Emergency Medicine, New York University School of Medicine North Shore Long Island Jewish Health System, Plainview, New York 11803, USA
    Diabetes Care 29:9-14. 2006
    ..The objective of this study was to characterize treatment patterns among patients with diabetes presenting with non-ST-segment elevation (NSTE) acute coronary syndromes (ACSs)...
  54. ncbi Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis
    Michael P Hudson
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 147:546-52. 2004
    ..We assessed whether elevated TnT levels are associated with the severity, etiology, and prognosis of HF in stable, ambulatory patients...
  55. ncbi Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, PA, Philadelphia, USA
    Eur Heart J 24:1763-70. 2003
    ..To examine differences in patient characteristics and outcomes in 19636 patients enrolled in the USA and 3027 patients enrolled in other countries undergoing intra-aortic balloon pump (IABP) counterpulsation...
  56. ncbi Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)
    Thaddeus R Tolleson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 92:330-3. 2003
    ..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
  57. ncbi Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes
    L Kristin Newby
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 41:31S-36S. 2003
    ..This paper will review the evolution of these important roles of troponin testing for risk stratification in ACS...
  58. ncbi Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
    Padma Kaul
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Am Coll Cardiol 41:371-80. 2003
    ..4 vs. 1.5). CONCLUSIONS: Quantitative ST and cTnT status are complementary in assessing risk among ACS patients and both should be employed to determine prognosis and assist in medical decision making...
  59. ncbi Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials
    David Hasdai
    Rabin Medical Center, Petah Tikva, Israel
    Am Heart J 145:73-9. 2003
    ..38-1.74) and 2.15 times greater risk of death/re-MI (95% CI 1.96-2.36). CONCLUSION: Mild-to-moderate HF is a frequent and ominous complication of MI, especially when it does not resolve or develops after admission...
  60. ncbi Risk stratification in acute coronary syndromes: the need for continued vigilance in "low-risk" patients
    Matthew J Levinsky
    Am Heart J 144:750-2. 2002
  61. ncbi Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative
    James W Hoekstra
    Ohio State University, Columbus, OH 43210, USA
    Acad Emerg Med 9:1146-55. 2002
    ..It is the intent of CRUSADE to improve patient care in the ED by tracking and encouraging compliance with evidence-based guidelines for the evaluation and management of NSTE ACS...
  62. ncbi Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
    Wayne B Batchelor
    Tallahassee Heart and Vascular Institute, Tallahassee Memorial Healthcare, Tallahassee, Fla 32308, USA
    Circulation 106:1470-6. 2002
    ..The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established...
  63. ncbi Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes
    Jassim Al Suwaidi
    Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circulation 106:974-80. 2002
    ..CONCLUSIONS: Patients presenting with ACS frequently have abnormal RF. Abnormal RF is a marker of adverse baseline clinical characteristics and is independently associated with increased risk of death and death/MI...
  64. ncbi Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
    Ronnier J Aviles
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44951, USA
    N Engl J Med 346:2047-52. 2002
    ..However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney...
  65. ncbi Prognostic significance of elevated troponin I after percutaneous coronary intervention
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, 30 Bond Street, Toronto, Ontario, Canada M5B 1W8
    J Am Coll Cardiol 39:1738-44. 2002
    ..We sought to assess the incidence and clinical significance of elevated cardiac troponin I (cTnI) after percutaneous coronary intervention (PCI)...
  66. ncbi Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial
    Sorin J Brener
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:377-86. 2002
    ..This study was designed to test the hypothesis that eptifibatide and reduced-dose tissue plasminogen activator (t-PA) will enhance infarct artery patency at 60 min in patients with acute myocardial infarction (AMI)...
  67. ncbi Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS
    Timo Lenderink
    Department of Cardiology, Thoraxcentre, Erasmus Medical Centre, Rotterdam, The Netherlands
    Am Heart J 147:865-73. 2004
    ..Specific dosing guidelines for combination with low-molecular weight heparin must be developed for patients who subsequently will undergo a PCI...
  68. ncbi Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Venu Menon
    Division of Cardiology, University of North Carolina at Chapel Hill, 27599, USA
    Chest 126:549S-575S. 2004
    ....
  69. ncbi Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jeffrey J Popma
    Interventional Cardiology, Brigham and Women s Hospital, 75 Francis St, Tower 2 3A Room 311, Boston, MA 02115, USA
    Chest 126:576S-599S. 2004
    ..In patients who undergo PCI with no other indication for systemic anticoagulation therapy, we recommend against routine use of vitamin K antagonists after PCI (Grade 1A)...
  70. ncbi Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..All patients with ACS should have CK-MB measurement to search for cardiac ischemia. Patients with elevated CK-MB should receive aggressive management commensurate with their increased risks...
  71. ncbi Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Regist
    Jason W Ryan
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 112:3049-57. 2005
    ..Using weekend status as an instrumental variable, we found no significant benefit to early catheterization, although we could not exclude an important risk reduction, particularly for catheterization within 12 hours of presentation...
  72. ncbi Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department
    W Brian Gibler
    University of Cincinnati College of Medicine, USA
    Ann Emerg Med 46:185-97. 2005
    ..Despite publication of the guidelines several years ago, many patients with UA/NSTEMI still do not receive guidelines-indicated therapy...
  73. ncbi Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopen
    E Magnus Ohman
    Division of Cardiology, Division of Hematology, and School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599 7075, USA
    J Thromb Thrombolysis 19:11-9. 2005
    ..IMPLICATIONS: The registry will provide valuable insights to the incidence and consequences of HIT and HITT that will enable improvements in diagnosis and treatment...
  74. ncbi Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns
    James W Hoekstra
    Department of Emergency Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Acad Emerg Med 12:431-8. 2005
    ....
  75. ncbi Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis
    Wei Ching Chang
    University of Alberta, Edmonton, Alberta T6G 2H7, Canada
    J Epidemiol Community Health 59:427-33. 2005
    ..The relative contributions of patient, hospital, and country level factors on clinical outcomes, however, remain unclear, and thus, was the objective of this study...
  76. ncbi Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Impleme
    Ali F Sonel
    Center for Health Equity Research and Promotion, Pittsburgh, PA, USA
    Circulation 111:1225-32. 2005
    ..It is unknown whether racial disparities exist for other treatments for non-ST-segment elevation acute coronary syndromes (NSTE ACS) and how different treatments affect outcomes...
  77. ncbi Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementatio
    Andra L Blomkalns
    Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0769, USA
    J Am Coll Cardiol 45:832-7. 2005
    ..We hypothesized that significant disparities in gender exist in the management of patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS)...
  78. ncbi Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE)
    JoAnne M Foody
    Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA
    Am J Cardiol 95:483-5. 2005
    ....
  79. ncbi Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction
    Hung Q Ly
    Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 95:383-6. 2005
    ..44, 95% confidence interval 0.23 to 0.85, p = 0.014)...
  80. ncbi Overcoming the challenges facing quality-improvement strategies for non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Am Fam Physician 70:1868, 1874, 1876. 2004
  81. ncbi Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy
    Alejandro Barbagelata
    Hospital Italiano, Buenos Aires, Argentina
    Am Heart J 148:795-802. 2004
    ..The standard 12-lead ECG provides a simple, economical means of risk stratification at discharge...
  82. ncbi Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative
    E Magnus Ohman
    Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Am Heart J 148:S34-9. 2004
    ..These ACC/AHA guidelines are intended to help physicians make appropriate decisions when diagnosing and treating patients with NSTE ACS...
  83. ncbi The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes
    Stefano Savonitto
    Department of Cardiology, Niguarda Hospital, Milan, Italy
    J Am Coll Cardiol 39:22-9. 2002
    ..The study investigated the relationship among creatine kinase (CK) elevations, clinical characteristics and cardiac events across the whole spectrum of acute coronary syndromes (ACS)...